Literature DB >> 10699370

Purine metabolism abnormalities in a hyperuricosuric subclass of autism.

T Page1, M Coleman.   

Abstract

A subclass of patients with classic infantile autism have uric acid excretion which is >2 S.D.s above the normal mean. These hyperuricosuric autistic individuals may comprise approx. 20% of the autistic population. In order to determine the metabolic basis for urate overexcretion in these patients, de novo purine synthesis was measured in the cultured skin fibroblasts of these patients by quantification of the radiolabeled purine compounds produced by incubation with radiolabeled sodium formate. For comparison, de novo purine synthesis in normal controls, in normouricosuric autistic patients, and cells from patients with other disorders in which excessive uric acid excretion is seen was also measured. These experiments showed that de novo purine synthesis is increased approx. 4-fold in the hyperuricosuric autistic patients. This increase was less than that found in other hyperuricosuric disorders. No unusual radiolabeled compounds (such as adenylosuccinate) were detected in these experiments, and no gross deficiencies of radiolabeled nucleotides were seen. However, the ratio of adenine to guanine nucleotides produced by de novo synthesis was found to be lower in the cells of the hyperuricosuric autistic patients than in the normal controls or the cells from patients with other disorders. These results indicate that the hyperuricosuric subclass of autistic patients have increased de novo purine synthesis, and that the increase is approximately that expected for the degree of urate overexcretion when compared to other hyperuricosuric disorders. No particular enzyme defect was suggested by either gross deficiency of a radiolabeled compound or the appearance of an unusual radiolabeled compound, and no potentially neurotoxic metabolites were seen. Although an enzyme defect responsible for the accelerated purine synthesis was not identified, the abnormal ratio of adenine to guanine nucleotides suggests a defect in purine nucleotide interconversion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699370     DOI: 10.1016/s0925-4439(99)00113-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

1.  Yeast AMP pathway genes respond to adenine through regulated synthesis of a metabolic intermediate.

Authors:  K Rébora; C Desmoucelles; F Borne; B Pinson; B Daignan-Fornier
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

2.  Genome-wide association of serum uric acid concentration: replication of sequence variants in an island population of the Adriatic coast of Croatia.

Authors:  Rebekah Karns; Ge Zhang; Guangyun Sun; Subba Rao Indugula; Hong Cheng; Dubravka Havas-Augustin; Natalija Novokmet; Dusko Rudan; Zijad Durakovic; Sasa Missoni; Ranajit Chakraborty; Pavao Rudan; Ranjan Deka
Journal:  Ann Hum Genet       Date:  2012-01-09       Impact factor: 1.670

3.  Global metabolic profiles in a non-human primate model of maternal immune activation: implications for neurodevelopmental disorders.

Authors:  Joseph C Boktor; Mark D Adame; Destanie R Rose; Cynthia M Schumann; Karl D Murray; Melissa D Bauman; Milo Careaga; Sarkis K Mazmanian; Paul Ashwood; Brittany D Needham
Journal:  Mol Psychiatry       Date:  2022-08-26       Impact factor: 13.437

4.  Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity.

Authors:  S A Masino; M Kawamura; C D Wasser; C A Wasser; L T Pomeroy; D N Ruskin
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

5.  Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiae.

Authors:  David Kowalski; Lakshmi Pendyala; Bertrand Daignan-Fornier; Stephen B Howell; Ruea-Yea Huang
Journal:  Mol Pharmacol       Date:  2008-07-08       Impact factor: 4.436

Review 6.  Uric acid changes in urine and plasma: an effective tool in screening for purine inborn errors of metabolism and other pathological conditions.

Authors:  R E Simoni; L N L Ferreira Gomes; F B Scalco; C P H Oliveira; F R Aquino Neto; M L Costa de Oliveira
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

7.  The G22A polymorphism of the ADA gene and susceptibility to autism spectrum disorders.

Authors:  Joe A Hettinger; Xudong Liu; Jeanette Jeltje Anne Holden
Journal:  J Autism Dev Disord       Date:  2007-03-06

8.  Urinary Essential Elements of Young Children with Autism Spectrum Disorder and their Mothers.

Authors:  Fatir Qureshi; James Adams; Devon Coleman; David Quig; Juergen Hahn
Journal:  Res Autism Spectr Disord       Date:  2020-02-06

9.  Metabolomics analysis of maternal serum exposed to high air pollution during pregnancy and risk of autism spectrum disorder in offspring.

Authors:  Ja Hyeong Kim; Qi Yan; Karan Uppal; Xin Cui; Chenxiao Ling; Douglas I Walker; Julia E Heck; Ondine S von Ehrenstein; Dean P Jones; Beate Ritz
Journal:  Environ Res       Date:  2021-02-04       Impact factor: 8.431

10.  Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model.

Authors:  Robert K Naviaux; Zarazuela Zolkipli; Lin Wang; Tomohiro Nakayama; Jane C Naviaux; Thuy P Le; Michael A Schuchbauer; Mihael Rogac; Qingbo Tang; Laura L Dugan; Susan B Powell
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.